Singapur - inglise - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - exenatide - injection, solution - 250mcg

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of:,- greater than or equal to 30 kg/m2 (obese) or,- greater than or equal to 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - dulaglutide, quantity: 1.5 mg - injection, solution - excipient ingredients: citric acid; water for injections; mannitol; polysorbate 80; sodium citrate dihydrate - type 2 diabetes mellitus: glycaemic control - trulicity is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: ? as monotherapy. ? in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations).,type 2 diabetes mellitus: reduction in risk of major adverse cardiovascular events - trulicity is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have: ? established cardiovascular disease or ? multiple cardiovascular risk factors

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide -

Euroopa Liit - inglise - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - byetta is indicated for treatment of type-2 diabetes mellitus in combination with:metformin;sulphonylureas;thiazolidinediones;metformin and a sulphonylurea;metformin and a thiazolidinedione;in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

food and drug administration - exenatide (unii: 9p1872d4ol) (exenatide - unii:9p1872d4ol) -

Euroopa Liit - inglise - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:metforminsulphonylureathiazolidinedionemetformin and sulphonylureametformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - exenatide - solution for injection - 250microgram/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk - exenatide - solution for injection - 250microgram/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - exenatide - solution for injection - 250microgram/1ml